Priscilla Brastianos, MD, a neuro-oncologist with the Mass General Brigham Cancer Institute and co-chair of the Alliance Neuro-Oncology Committee (IMAGE)
Caption
“Patients with recurrent or progressive high-grade meningiomas have historically had very few treatment options, and most prior trials of medical therapy have been disappointing,” said senior author Priscilla Brastianos, MD, a neuro-oncologist with the Mass General Brigham Cancer Institute and co-chair of the Alliance Neuro-Oncology Committee.
Noting that the trial was the first national study to enroll patients based on mutational testing, Dr. Brastianos said that the research “shows that genomically driven trials for patients with meningioma are feasible and that targeted therapy may improve outcomes for patients with specific genetic mutations.”
Credit
Mass General Brigham
Usage Restrictions
none
License
Original content